Evidence map›Paper›PMID 26449749›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2015

Three-Dimensional Vascular Network Assembly From Diabetic Patient-Derived Induced Pluripotent Stem Cells.

Xin Yi Chan, Rebecca Black, Kayla Dickerman, Joseph Federico, Mathieu Lévesque, Jeff Mumm, Sharon Gerecht

Open access · bronzeAbstract readVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Vascularized Organoids: A More Complete Model.International journal of stem cells · 2021
    Review
  12. iScience · 2021
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xin Yi ChanFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Rebecca BlackFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Kayla DickermanFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Joseph FedericoFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Mathieu LévesqueFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Jeff MummFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Sharon GerechtFrom the Department of Chemical and Biomolecular Engineering, Institute for NanoBioTechnology (X.Y.C., R.B., K.D., J.F., S.G.) and Department of Materials Science and Engineering (S.G.), Johns Hopkins University, Baltimore, MD; and Department of Ophthalmology, Wilmer Eye Institute (M.L., J.M.) and McKusick-Nathans Institute of Genetic Medicine (M.L., J.M.), Johns Hopkins University School of Medicine, Baltimore, MD.
Johns Hopkins University · US

Funding

Engineered Stem Cell Microenvironments for controlled VasculogenesisR01HL107938 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GERECHT, SHARON · 2011 to 2015
$2.1M
Controlling endothelial fate and vascular assembly from pluripotent stem cellsF32HL128038 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHAN, XIN YI · 2015 to 2017
$175k
NHLBI NIH HHS F32 HL128038NHLBI NIH HHS R01 HL107938NHLBI NIH HHS R01HL107938
6 · The paper itself

Abstract

objectiveIn diabetics, hyperglycemia results in deficient endothelial progenitors and cells, leading to cardiovascular complications. We aim to engineer 3-dimensional (3D) vascular networks in synthetic hydrogels from type 1 diabetes mellitus (T1D) patient-derived human-induced pluripotent stem cells (hiPSCs), to serve as a transformative autologous vascular therapy for diabetic patients. APPROACH AND

resultsWe validated and optimized an adherent, feeder-free differentiation procedure to derive early vascular cells (EVCs) with high portions of vascular endothelial cadherin-positive cells from hiPSCs. We demonstrate similar differentiation efficiency from hiPSCs derived from healthy donor and patients with T1D. T1D-hiPSC-derived vascular endothelial cadherin-positive cells can mature to functional endothelial cells-expressing mature markers: von Willebrand factor and endothelial nitric oxide synthase are capable of lectin binding and acetylated low-density lipoprotein uptake, form cords in Matrigel and respond to tumor necrosis factor-α. When embedded in engineered hyaluronic acid hydrogels, T1D-EVCs undergo morphogenesis and assemble into 3D networks. When encapsulated in a novel hypoxia-inducible hydrogel, T1D-EVCs respond to low oxygen and form 3D networks. As xenografts, T1D-EVCs incorporate into developing zebrafish vasculature.

conclusionsUsing our robust protocol, we can direct efficient differentiation of T1D-hiPSC to EVCs. Early endothelial cells derived from T1D-hiPSC are functional when mature. T1D-EVCs self-assembled into 3D networks when embedded in hyaluronic acid and hypoxia-inducible hydrogels. The capability of T1D-EVCs to assemble into 3D networks in engineered matrices and to respond to a hypoxic microenvironment is a significant advancement for autologous vascular therapy in diabetic patients and has broad importance for tissue engineering.

Indexed as

Cell DifferentiationNeovascularization, PathologicAnimalsAnimals, Genetically ModifiedAntigens, CDCadherin 5CadherinsCase-Control StudiesCell HypoxiaCell LineCell SeparationCell ShapeDiabetes Mellitus, Type 1Endothelial Progenitor CellsGreen Fluorescent ProteinsHeterograftsacetyl-LDLAntigens, CDCadherin 5CadherinsGreen Fluorescent ProteinsHyaluronic AcidHydrogelsLipoproteins, LDLNitric Oxide Synthase Type IIINOS3 protein, humanTumor Necrosis Factor-alphavon Willebrand Factordiabetes mellitusendothelial cellshydrogelsinduced pluripotent stem cellsvascular networks

Identifiers

PMID26449749
PMCPMC4603427
OpenAlexW2152895485

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.